4DMedical The Worst Performer on The ASX 200 Today: Key Moving Average Flips

4DMedical shares (ASX: 4DX) wrapped up the first trading day of the week at the bottom of the ASX 200 leaderboard, falling back 6.22%, after once again failing to clear resistance.

The 4DX share price closed out the session at A$4.07, down A$0.27 or 6.22%, in a move that saw the stock fall below the 200-day SMA at A$4.118. This long-term trendline is widely regarded by traders that use technical analysis as a dividing line between a structurally bullish and structurally bearish trend, and marks a possible shift of sentiment.

On multiple occasions, 4DX has attempted to push through the A$4.30 to A$4.40 range, only to be turned back by what appears to be a well-established overhead supply zone. With the 200-day SMA now sitting above the current price rather than below it, that resistance band has effectively widened, giving short sellers additional technical cover to maintain or extend their positions. The stock remains among the most heavily shorted on the entire ASX 200, with short interest exceeding 12% of total issued shares.

Recent Fundamentals

The most recent full-year financial results for FY26 highlighted a company growing its top line at a meaningful pace but burning cash at a rate that continues to test market patience. Operating revenue came in at approximately A$7.1 million to A$7.2 million, representing year-over-year growth of roughly 21% to 23%. Global scan volumes surged 77% to more than 344,000 scans across 540 sites worldwide, a figure that underscores genuine and accelerating clinical adoption of the technology.

The problem, from a valuation standpoint, is the gap between that revenue base and the company’s net loss, which expanded dramatically to A$204.4 million in FY26, up from A$30.1 million in the prior year. The widening loss reflects heavy investment in commercialization infrastructure, the integration of artificial intelligence acquisitions, and the cost of scaling a global SaaS operation from a relatively small revenue base. With a market capitalisation exceeding A$2.5 billion, 4DX is trading at a revenue multiple that demands near-flawless execution and sustained high-growth delivery for years to come.

On the positive side of the ledger, 4DMedical holds a cash balance of approximately A$278 million to A$283 million following recent capital raises. That war chest provides the company with a meaningful runway, likely several years at current burn rates, to pursue its commercial strategy without being forced into dilutive equity raises in the near term.

The Setup From Here

The technical setup for 4DX is leaning bearish in the near term, although momentum has swung various times this side of calendar 2026 after a huge run through the second half of calendar 2025.

Losing the 200-day SMA, and firming up a resistance zone is far from the perfect start to the week, yet this is a stock that remains 15.63% higher over the past month of trading. For the bulls to regain control, 4DX would need to reclaim A$4.118 convincingly and then break through the A$4.30 to A$4.40 supply zone. The YTD decline of 10.35% sits against a 12 month gain of 80.89%, highlighting the extend of the rally last year, and putting some perspective to recent action.

With more than 12% of shares sold short, the stock carries significant short-covering potential if there is a meaningful upside catalyst, yet without, buyers remain firmly challenged to break free. From a fundamental perspective, the investment case rests almost entirely on the pace at which 4DMedical can convert its clinical validation and commercial partnerships into recognised recurring revenue. The 77% jump in scan volumes is genuinely encouraging and suggests the technology is finding real-world acceptance among clinicians.

The question now is whether the rate of acceleration in revenue can keep pace with a stock that seemingly has plenty priced in off the back of last year’s rally of ~1800% through the second half of the calendar.